Chemoimmunotherapy outcomes and prognostic factors in patients with advanced, low PD-L1-expressing non-small cell lung cancer.

Abstract

Chemoimmunotherapy is recommended for patients with non-small cell lung cancer (NSCLC) with low programmed cell death-ligand 1 (PD-L1) expression, but the effect of additional immunotherapy is heterogeneous in this population. To identify patients who do not benefit from the addition of immune checkpoint inhibitors (ICIs) to chemotherapy, we conducted a retrospective study at 19 institutions in Japan. We analyzed 851 patients with advanced NSCLC with a PD-L1 tumor proportion score (TPS) of 1-49% who received chemoimmunotherapy (n = 504) or chemotherapy (n = 347) between March 2017 and June 2022. After adjustment by propensity score matching, median overall survival (OS) was 22.3 months in the chemoimmunotherapy group and 17.0 months in the chemotherapy alone group (P = 0.01). Multivariate analysis showed that among 12 clinical factors, liver metastases (P = 0.001) and history of antibiotic use (P = 0.02) were independently associated with shorter OS in the chemoimmunotherapy group. Patients with liver metastases (OS, P = 0.4; PFS, P = 0.06) or history of antimicrobial use (OS, P = 0.24; PFS, P = 0.09) did not benefit from the addition of ICI to chemotherapy. Patients with a history of antimicrobial use experienced more severe pneumonitis with chemoimmunotherapy than all patients (P = 0.04). This cohort study showed that liver metastases or prior antimicrobial therapy are the most important clinical factors that attenuate the efficacy of chemoimmunotherapy in patients with low PD-L1 expression.